ISATORIBINE, a guanosine analog, is an immunopotentiating agent. It is a selective agonist of toll‐like receptor 7, a pattern-recognition receptor that activates the innate immune response.

Iolixanic Acid is triiodophenoxyalkoxyalkanoic acid derivative patented by Bracco Industria Chimica S.p.A. as a diagnostic agent for cholecystography and urinary tract imaging

Iosarcol (also known as Melitrast) is an iodinated nonionic monomeric contrast medium patented by Dr. Franz Koehler and Chemie KG for radiographic imaging.

Ioglucomide is triiodoanilide derivative patented by Mallinckrodt, Inc. as nonionic x-ray contrast media for myelography. In preclinical studies the efficacy of ioglucomide and metrizamide were comparable. However, acute toxicity after intravenous injection or installation into cerebrospinal fluid was significantly less for ioglucomide. Also, in contrast to metrizamide, ioglucomide produced no evidence of any type of convulsive activity after subarachnoid administration.

response, while the remaining 7 patients were too far advanced to respond to these treatments. Benaxibine (also known as paraaminobenzoic acid-N-xyloside or K-247) was developed as an antitumor drug. Benaxibine participated in several clinical trials. However, for the positive application of the drug further studies were needed.

Dramedilol is a beta-blocker with peripheral vasodilative activity. Dramedilol had been under investigation for the treatment of hypertension. However, this study was discontinued.

Andrographolide, a diterpenoid, is known for its anti-inflammatory effects. It can be isolated from various plants of the genus Andrographis, commonly known as 'creat'. Andrographolide has been tested for its anti-inflammatory effects in various stressful conditions, such as ischemia, pyrogenesis, arthritis, hepatic or neural toxicity, carcinoma, and oxidative stress. Apart from its anti-inflammatory effects, andrographolide also exhibits immunomodulatory effects by effectively enhancing cytotoxic T cells, natural killer (NK) cells, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). The properties of andrographolide, such as its ability to induce apoptosis of cancer cells and inhibition of DTH, its anti-oxidative and cytoprotective effect, and its ability to enhance CTLs and NK cell activation makes it a potent antiviral agent. Andrographolide inhibited the growth of human breast, prostate, and hepatoma tumors. Andrographolide could be a potent anticancer agent when used in combination with other chemotherapeutic agents.

Mindodilol (also known as BM 12,434) was investigated as a beta-adrenoceptor-blocking agent. This drug was potentially useful for the treatment of both coronary heart disease and of arterial hypertension. However, information about the further development of this drug is not available.

Quillifoline is a quinolizine derivative patented by N. V. Koninklijke Pharmaceutische Fabrieken voorheen Brocades-Stheeman & Pharmacia as adrenolytic, sedative, and vasodilator.